SynthesisClinical and experimental rheumatology
Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.
Synthesis in Clinical and experimental rheumatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Trial
- Telitacicept versus belimumab for the treatment of systemic lupus erythematosus: a network meta-analysis and cost-effectiveness analysis.Lupus science & medicine · 2026Article
- Evaluation of the classification performance and cost-effectiveness of classification criteria in children with systemic lupus erythematosus.Frontiers in pediatrics · 2026Article
- Real-World Prevalence, Incidence and Management of Systemic Lupus Erythematosus in Germany: A Retrospective Claims Data Analysis.Rheumatology and therapy · 2025Article
- Unfavorable Outcomes Associated With Glucocorticoid Use in Current Standard-of-Care Management of Systemic Lupus Erythematosus in Canada.ACR open rheumatology · 2024Article
- Disparities in Lupus and the Role of Social Determinants of Health: Current State of Knowledge and Directions for Future Research.ACR open rheumatology · 2023Review
- The Economic Burden of Lupus Nephritis: A Systematic Literature Review.Rheumatology and therapy · 2022Review
- Increase in direct costs for health systems due to lupus nephritis: the case of Colombia.Einstein (Sao Paulo, Brazil) · 2022Article
- The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization.Rheumatology and therapy · 2021Article
- 'When I asked for help and support it was not there': current NHS employment practice and its impact on people with systemic lupus erythematosus.Rheumatology advances in practice · 2021Article
- The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.Seminars in arthritis and rheumatism · 2020Observational
- Burden of Systemic Lupus Erythematosus on Work Productivity and Daily Living Activity: A Cross-Sectional Study Among Malaysian Multi-Ethnic Cohort.Archives of rheumatology · 2020Article
- Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.Lupus science & medicine · 2020Observational
- Observational
- The SLE-key test serological signature: new insights into the course of lupus.Rheumatology (Oxford, England) · 2018Article
- Rare diseases under different levels of economic analysis: current activities, challenges and perspectives.RMD open · 2018Review
- Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases.Current rheumatology reports · 2017Review
- Effective Self-Management Interventions for Patients With Lupus: Potential Impact of Peer Mentoring.The American journal of the medical sciences · 2017Review
- Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008-2012.Reumatologia · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Systemic lupus erythematosus (SLE) is a chronic, disabling, progressive disease, with many associated comorbidities, affecting patients during prime working years resulting in a high economic burden on society, producing high direct, indirect and intangible costs. In this article, our goals are two-fold. First, we review and discuss studies published in the period 2002-2012 concerning costs of SLE and point out gaps in the published literature. Second, we propose further research studies to advance our understanding of the economic perspective in SLE in the current area of new and emerging therapies. The literature evaluating disease costs in SLE remains limited and to date has only included a small number of countries. Despite these limitations, available studies indicate that SLE has significant socio-economic ramifications. Future studies are needed, especially to assess novel biologic therapies which have been made available or currently under investigation for SLE. An interesting approach in these new economic evaluations in SLE may be represented by the selection of the targets of the treatment to include in the cost-effectiveness and cost-utility analyses. Future treat-to-target strategies will likely include evaluation of their pharmacoeconomic implications.
Indexed as
Identifiers
23072767PMC3714226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.